pERK Expression in Erlotinib-treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From the Randomized AIO-PK0104 Phase III Trial

被引：0
|
作者：
Boeck, S. [1 ,2 ]
Ormanns, S. [3 ]
Laubender, R. P. [4 ]
Jung, A. [3 ]
Siveke, J. T. [5 ]
Haas, M. [1 ,2 ]
Kirchner, T. [3 ]
Heinemann, V. [1 ,2 ]
机构：
[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-8000 Munich, Germany
[2] Ctr Comprehens Canc, Munich, Germany
[3] Univ Munich, Dept Pathol, Munich, Germany
[4] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany
[5] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, D-8000 Munich, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72275-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477
引用
收藏
页码：148 / 148
页数：1
相关论文
共 50 条
  • [21] Randomized, cross-over phase III study of gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer - a multicenter trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO)
    Boeck, S.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Kettner, E.
    Maerten, A.
    Winkelmann, C.
    Klein, S.
    Kojouharoff, G.
    Jung, A.
    Heinemann, V
    ONKOLOGIE, 2010, 33 : 25 - 25
  • [22] Vandetanib versus erlotinib in patients with previously treated advanced NSCLC: a randomized, double-blind phase III trial (ZEST)
    Natale, Ronald B.
    Thongprasert, Sumitra
    Greco, F. Anthony
    Thomas, Michael
    Tsai, Chun-Ming
    Sunpaweravong, Patrapim
    Ferry, David
    Langmuir, Peter
    Gogov, Sven
    Rowbottom, Jacqui A.
    Goss, Glenwood D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S358 - S358
  • [23] Analysis of prognostic factors in patients with advanced pancreatic cancer: Subgroup analysis of a randomized phase III trial comparing single-agent gemcitabine to the gemcitabine plus cisplatin combination.
    Boeck, S
    Hinke, A
    Wilkowski, R
    Heinemann, V
    Grosshadern, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [24] Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
    Ioka, Tatsuya
    Okusaka, Takuji
    Ohkawa, Shinichi
    Boku, Narikazu
    Sawaki, Akira
    Fujii, Yosuke
    Kamei, Yoichi
    Takahashi, Satori
    Namazu, Katsushi
    Umeyama, Yoshiko
    Bycott, Paul
    Furuse, Junji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (05) : 439 - 448
  • [25] Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
    Natale, Ronald B.
    Thongprasert, Sumitra
    Greco, F. Anthony
    Thomas, Michael
    Tsai, Chun-Ming
    Sunpaweravong, Patrapim
    Ferry, David
    Mulatero, Clive
    Whorf, Robert
    Thompson, Joyce
    Barlesi, Fabrice
    Langmuir, Peter
    Gogov, Sven
    Rowbottom, Jacqui A.
    Goss, Glenwood D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1059 - 1066
  • [26] Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Boeck, S. H.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Kettner, E.
    Maerten, A.
    Winkelmann, C.
    Klein, S.
    Kojouharoff, G.
    Jung, A.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [27] Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
    Scagliotti, Giorgio V.
    Krzakowski, Maciej
    Szczesna, Aleksandra
    Strausz, Janos
    Makhson, Anatoly
    Reck, Martin
    Wierzbicki, Rafal F.
    Albert, Istvan
    Thomas, Michael
    Abrao Miziara, Jose Elias
    Papai, Zsolt S.
    Karaseva, Nina
    Thongprasert, Sumitra
    Dalmau Portulas, Elsa
    von Pawel, Joachim
    Zhang, Ke
    Selaru, Paulina
    Tye, Lesley
    Chao, Richard C.
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2070 - 2078
  • [28] Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Goss, G. D.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Gogov, S.
    Rowbottom, J. A.
    Natale, R. B.
    EJC SUPPLEMENTS, 2009, 7 (02): : 506 - 506
  • [29] Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS)
    Nobuyuki Katakami
    Toshihide Yokoyama
    Satoshi Morita
    Tatsuro Okamoto
    Yoshiko Urata
    Yoshihiro Hattori
    Yasuo Iwamoto
    Yuki Sato
    Norihiko Ikeda
    Toshiaki Takahashi
    Haruko Daga
    Tetsuya Oguri
    Yasuhito Fujisaka
    Kazumi Nishino
    Shunichi Sugawara
    Toshiyuki Kozuki
    Masahide Oki
    Nobuyuki Yamamoto
    Kazuhiko Nakagawa
    International Journal of Clinical Oncology, 2023, 28 : 79 - 88
  • [30] Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS)
    Katakami, Nobuyuki
    Yokoyama, Toshihide
    Morita, Satoshi
    Okamoto, Tatsuro
    Urata, Yoshiko
    Hattori, Yoshihiro
    Iwamoto, Yasuo
    Sato, Yuki
    Ikeda, Norihiko
    Takahashi, Toshiaki
    Daga, Haruko
    Oguri, Tetsuya
    Fujisaka, Yasuhito
    Nishino, Kazumi
    Sugawara, Shunichi
    Kozuki, Toshiyuki
    Oki, Masahide
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (01) : 79 - 88
12345